[논문]오적산 병용투여가 혈당강하 치료를 받고 있는 제2형 당뇨병 환자의 혈당에 미치는 영향

이민승; 정수민; 오승현; 이한영; 임형근; 안영민; 안세영; 이병철

doi:10.22246/jikm.2021.42.1.40

오적산 병용투여가 혈당강하 치료를 받고 있는 제2형 당뇨병 환자의 혈당에 미치는 영향
A Retrospective Study on the Effect of the Co-Administration of Ojeok-san and Hypoglycemic Agents on Blood Glucose Levels in Type 2 Diabetes Mellitus 원문보기

대한한방내과학회지 = The journal of internal Korean medicine, v.42 no.1, 2021년, pp.40 - 52

이민승 (경희대학교 대학원 임상한의학과) , 정수민 (경희대학교 대학원 임상한의학과) , 오승현 (경희대학교 대학원 임상한의학과) , 이한영 (경희대학교 대학원 임상한의학과) , 임형근 (경희대학교 대학원 임상한의학과) , 안영민 (경희대학교 대학원 임상한의학과) , 안세영 (경희대학교 대학원 임상한의학과) , 이병철 (경희대학교 대학원 임상한의학과)

Abstract ▼ AI-Helper

Objective: This study was conducted to investigate the hypoglycemic effect and safety of Ojeok-san in patients with type 2 Diabetes Mellitus. Methods: We investigated type 2 diabetes mellitus patients at Kyung-Hee University Korean Medical Hospital who were administered Ojeok-san for at least one day between January 2012 and September 2020, basal characteristics and laboratory tests were reviewed retrospectively. The hypoglycemic effect of Ojeok-san was assessed by comparing fasting blood sugar (FBS) and two hours post-prandial plasma glucose (PP2) levels from before and after taking Ojeok-san. Subgroup analyses were conducted according to baseline hypoglycemic treatments and glycated hemoglobin levels (< or ≥6.5%). The safety of Ojeok-san was assessed by comparing levels of aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, blood urea nitrogen, and creatinine. Results: After Ojeok-san administration, FBS and PP2 were significantly reduced to an average of 14.33 mg/dL and 27.67 mg/dL respectively. In the subgroup analysis, PP2 in patients receiving metformin mono therapy was significantly reduced to 28.67 mg/dL, and those receiving a dual therapy of metformin and DPP-4 inhibitor, it was significantly reduced to 32.33 mg/dL. In patients with glycated hemoglobin of lower than 6.5%, FBS was significantly reduced to 12.20 mg/dL, and both FBS and PP2 were significantly reduced, to 15.50 mg/dL and 40.00 mg/dL, respectively, in those with glycated hemoglobin levels of more than 6.5%. The safety profile showed no significant difference after Ojeok-san administration. Conclusions: Ojeok-san has significant hypoglycemic effects in patients with type 2 diabetes mellitus who are also taking hypoglycemic agents.

주제어

표/그림 (11)

표 Table 1. Composition of Ojeok-san
그림 Fig. 1. Flow chart of selection process. n : number, OJS : Ojeok-san
표 Table 2. Baseline Characteristics of Participants
그림 Fig 2. Change in blood glucose before and after coadministration of Ojeok-san and hypoglycemic agents. FBS : fasting blood sugar, PP2 : 2 hours postprandial plasma glucose
표 Table 3. Hypoglycemic Treatment of Participants
표 Table 4. Comparison of Blood Glucose before and After administration of Ojeok-san with Hypoglycemic Agents
그림 Fig 3. Subgroup analyses of blood glucose before and after administration of Ojeok-san with hypoglycemic agents - hypoglycemic treatment. FBS : fasting blood sugar, PP2 : 2 hours post-prandial plasma glucose, Met : Metformin, DPP4i : Dipeptidyl peptidase-4 inhibitor
표 Table 5. Subgroup Analyses of Blood Glucose before and after Administration of Ojeok-san with Hypoglycemic Agents -Hypoglycemic Treatment
그림 Fig. 4. Subgroup analyses of blood glucose before and after administration of Ojeok-san with hypoglycemic agents - HbA1c. FBS : fasting blood sugar, PP2 : 2 hours post-prandial plasma glucose, HbA1c : Glycated hemoglobin
표 Table 6. Subgroup Analyses of Blood Glucose before and after Administration of Ojeok-san with Hypoglycemic Agents - HbA1c
표 Table 7. Comparison of Liver and Kidney Function before and after Administration of Ojeok-san with Hypoglycemic Agents

참고문헌 (22)

보건복지부, 질병관리청. 2019 국민건강통계. 청주: 질병관리본부; 2020, p. 171.
Diabetes guideline committee. Treatment guideline for diabetes 2019. Seoul: Korean Diabetes Association; 2019, p. 25, 35, 57-64, 142-3.
보건복지부. 2017년 한방의료이용 및 한약소비실태조사. 서울: 한약진흥재단; 2018, p. 25, 47.
Korean Diabetes Association. Diabetes Fact Sheet in Korea 2020. Seoul: Korean Diabetes Association; 2020.
남산당편집국. 對譯證脈,方藥合編, 서울: 남산당; 2003, p. 136-7.
건강보험심사평가원. 2019 급여의약품 청구 현황. 원주: 건강보험심사평가원; 2020, p. 73.
Lee NH, Ha HK, Lee HY, Jung DY, Choi JY, Lee JK, et al. Analysis of Studies on Ojeok-san for Establishment of Evidence Based Medicine. The Korean Journal of Oriental Medical Prescription 2008;16(2):1-9.
Kim JH, Soh KS, Jeong CG, Kim KH. Effects of Ojuck-san on Hyperlipidemia in Rats. The Korean Society For Oriental Preventive Medicine 2004;8(2):185-202.
Choi HM, Moon SO, Lee HH, Lee HD. Inhibitory effect of by Ojeok-san lipid accumulation in high fat diet-induced obesity mice and 3T3-L1 adipocytes. Kor J Herbol 2015;30(4):121-8.

원문보기 상세보기
건강보험심사평가원. 2020년 상반기 진료비 주요통계. 원주: 건강보험심사평가원; 2020, p. 40.
건강보험심사평가원. 2019년 진료비 주요통계. 원주: 건강보험심사평가원; 2020, p. 40.
Korean Diabetes Association. Diabetes Fact Sheet in Korea 2018. Seoul: Korean Diabetes Association; 2018.
Lee SI. Cheon Jin Chubang Haesul. 1st ed. Seoul: Seongbosa; 1987, p. 118.
Yun JY, Yun YG. A Prescriptional Study of Ojeoksan on Clinical Application. Herbal Formula Science 2012;20(2):153-64.

원문보기 상세보기
Shin HR, Park KT, Yeom SR, Kwon YD. Safety of Ojeok-san Extract Powder and Soft Extract in Healthy Male Volunteers, Single Center, Randomized Controlled, Cross-over Study. Journal of Korean Medicine Rehabilitation 2019;29(1):63-73.

원문보기 상세보기
Park JK, Chae WS. Studies on the Effects of Administration per oral and Aqua - acupuncture with Ojucksan Extract Granule on the pain to mice. J Korean Acupunct Moxib Soc 1992;9(1):273-91.
Han BH, Yoon JJ, Kim HY, Ahn YM, Hong MH, Son CO. et al. Inhibitory Effects of Ojeoksan on TNF-α-induced Vascular Inflammation in Human Umbilical Vein Endothelial Cells. Kor J Herbol 2018;33(4):59-67.

원문보기 상세보기
Yoo SR, Jeong SJ, Kim YJ, Lim HS, Jin SE, Jeon WY, et al. Effects of water and ethanol extracts from Ojeok-san on inflammation and its related diseases. Korean J Orient Int Med 2012;33(4):418-28.
Jeon MH, Baek SH, Sin SW, Lee YS. A study on the effect of Ojeok-san on annihilation of uterine myomal cell and cell apoptosis. The Journal of Oriental Gynecology 2003;16(2):45-55.
Kim JW, Han SH, Jeong BJ, Woo SH, Kim BC, Kim YH, et al. A Case Report of Diabetic Hyperlipidemia in a Patient with Cerebral Infarction Treated with Ojeok-san. Korean J Orient Int Med 2005;26(1):275-80.
Rangwala SM, Lazar MA. Peroxisome proliferator -activated receptor gamma in diabetes and metabolism. Trends in pharmacological sciences 2004;25(6):331-6.

상세보기
Patel S, Santani D. Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. Pharmacological reports 2009;61(4):595-603.

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증